{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:30:04Z","timestamp":1648852204042},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,5,18]],"date-time":"2014-05-18T00:00:00Z","timestamp":1400371200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11899-014-0214-5","type":"journal-article","created":{"date-parts":[[2014,5,17]],"date-time":"2014-05-17T05:46:28Z","timestamp":1400305588000},"page":"217-221","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemotherapy Only in Early Stage Hodgkin Lymphoma: More Relapses but the Same Survival \u2013 What to Do?"],"prefix":"10.1007","volume":"9","author":[{"given":"Joseph M","family":"Connors","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,18]]},"reference":[{"key":"214_CR1","first-page":"299","volume":"63","author":"MV Peters","year":"1950","unstructured":"Peters MV. A study in survival of Hodgkin's disease treated radiologically. Am J Roentgenol. 1950;63:299\u2013311.","journal-title":"Am J Roentgenol"},{"key":"214_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1148\/78.4.553","volume":"78","author":"HS Kaplan","year":"1962","unstructured":"Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 1962;78:553\u201361.","journal-title":"Radiology"},{"key":"214_CR3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","volume":"73","author":"VT Devita Jr","year":"1970","unstructured":"Devita Jr VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881\u201395.","journal-title":"Ann Intern Med"},{"key":"214_CR4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.1986.4.9.1295","volume":"4","author":"DL Longo","year":"1986","unstructured":"Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4:1295\u2013306.","journal-title":"J Clin Oncol"},{"key":"214_CR5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.1986.4.6.830","volume":"4","author":"P Valagussa","year":"1986","unstructured":"Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 1986;4:830.","journal-title":"J Clin Oncol"},{"key":"214_CR6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM198801143180203","volume":"318","author":"MA Tucker","year":"1988","unstructured":"Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988;318:76\u201381.","journal-title":"N Engl J Med"},{"key":"214_CR7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","volume":"36","author":"G Bonadonna","year":"1975","unstructured":"Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252\u20139.","journal-title":"Cancer"},{"key":"214_CR8","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478\u201384.","journal-title":"N Engl J Med"},{"key":"214_CR9","first-page":"281a","volume":"20","author":"V Bonfante","year":"2001","unstructured":"Bonfante V, Viviani S, Devizzi L, Santoro A, Di Russo A, Zanini M, et al. Ten years experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved field (IFRT) in early-stage Hodgkin's disease. Proc Amer Soc Clin Oncol. 2001;20:281a. abstract 1120.","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"214_CR10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","volume":"357","author":"C Ferme","year":"2007","unstructured":"Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357:1916\u201327.","journal-title":"N Engl J Med"},{"key":"214_CR11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","volume":"79","author":"T Girinsky","year":"2006","unstructured":"Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270\u20137.","journal-title":"Radiother Oncol"},{"key":"214_CR12","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","volume":"26","author":"BA Campbell","year":"2008","unstructured":"Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26:5170\u20134.","journal-title":"J Clin Oncol"},{"key":"214_CR13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin lymphoma. N Engl J Med. 2010;363:640\u201352.","journal-title":"N Engl J Med"},{"key":"214_CR14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","volume":"366","author":"RM Meyer","year":"2012","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366:399\u2013408. The pivotal study demonstrating that the large majority of patients with limited-stage Hodgkin lymphoma do not require radiation.","journal-title":"N Engl J Med"},{"key":"214_CR15","first-page":"369","volume":"112","author":"J Radford","year":"2008","unstructured":"Radford J, O'Doherty M, Barrington S, Qian W, Patrick P, Coltart S, et al. Results of the 2nd planned interim analysis of the RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin Lymphoma and a \u2018negative\u2019 FDG-PET Scan after 3 Cycles ABVD. ASH Ann Meet Abstr. 2008;112:369. The first study demonstrating that PET guidance can be used to eliminate most radiation from the treatment of patients with limited-stage Hodgkin lymphoma.","journal-title":"ASH Ann Meet Abstr"},{"key":"214_CR16","first-page":"549","volume":"120","author":"MP Andre","year":"2012","unstructured":"Andre MP, Reman O, Federico M, Girinski T, Brice P, Brusamolino E, et al. Interim analysis of the randomized Eortc\/Lysa\/Fil Intergroup H10 trial on early PET-Scan driven treatment adaptation in stage I\/II Hodgkin Lymphoma. ASH Ann Meet Abstr. 2012;120:549. The large prospective European cooperative group trial showing that 80% of patients with limited-stage Hodgkin lymphoma reach a PET-negative state after two cycles of ABVD.","journal-title":"ASH Ann Meet Abstr"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-014-0214-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-014-0214-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-014-0214-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T15:20:19Z","timestamp":1565450419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-014-0214-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,18]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1007\/s11899-014-0214-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,18]]}}}